R&D Tax Credits: Global Overview — US Section 41, UK RDEC, French CIR

Summary

There is no single global R&D credit — each country defines its own eligible activities, rates, caps, and documentation, and companies must claim independently in every jurisdiction where they perform R&D. As of mid-2026 the six largest regimes are: US Section 41 credit (20% regular / 14% ASC) plus Section 174A immediate domestic expensing restored by OBBBA, with Rev. Proc. 2025-28 setting a July 6, 2026 deadline for eligible small businesses to amend 2022-2024 returns; UK merged RDEC (20%, net ~15%) and ERIS (27% for 30%-intensity loss-making SMEs), with mandatory agent registration and a targeted Advance Assurance pilot both starting 18 May 2026; France CIR (30% on the first EUR 100M), confirmed unchanged by the 2026 Finance Law; Canada SR&ED (35% refundable), where Budget 2025 raised the enhanced expenditure limit to CAD 6M, reinstated capital expenditures, and extended the enhanced rate to certain public corporations; Germany Forschungszulage (25-35% on up to EUR 12M from 2026); and Australia RDTI (43.5% refundable for SMEs). [src1, src7, src9, src10, src11]

Rule

Companies performing qualifying research and development activities should claim available R&D tax credits in every jurisdiction where they operate, following each country's specific eligibility tests, documentation requirements, and filing deadlines. The six largest R&D incentive regimes — US Section 41 credit (plus Section 174A immediate expensing restored by OBBBA in July 2025), UK merged RDEC scheme (20% credit from April 2024), France CIR (30% on first EUR 100M, confirmed unchanged in the 2026 Finance Law), Canada SR&ED (35% refundable; Budget 2025 raised the enhanced expenditure limit to CAD 6M and reinstated capital-expenditure eligibility for property acquired on/after Dec 16, 2024), Germany Forschungszulage (25-35% on up to EUR 12M from 2026), and Australia RDTI (43.5% refundable for SMEs) — collectively account for over 80% of global R&D tax support. Each regime has distinct qualifying activity tests, eligible expense categories, and interaction effects with other tax provisions that must be evaluated independently. [src1, src7, src10]

Evidence

Thirty-four of 38 OECD countries offered R&D tax incentives in 2024, with the average implied tax subsidy rate at 16% for large firms and 19% for SMEs. France provides the second-most generous relief globally at 36% implied subsidy rate, behind only Portugal at 39%. The US Section 41 credit alone supports approximately $15-20 billion in annual claims, with the OBBBA restoring immediate domestic R&D expensing effective for tax years beginning after December 31, 2024. The UK's merged RDEC scheme processes over GBP 7 billion in annual claims from approximately 90,000 companies. Canada's SR&ED program distributes CAD 3-4 billion annually; Budget 2025 (tabled November 2025) finalized the largest expansion in decades — raising the enhanced-credit expenditure limit from CAD 3M to CAD 6M (so a CCPC can now earn up to CAD 2.1M in refundable credit), lifting the taxable-capital phase-out range from CAD 10M–50M to CAD 15M–75M, reinstating capital-expenditure eligibility (excluded since 2014) for property acquired on or after Dec 16, 2024, and for the first time extending the enhanced 35% refundable credit to certain eligible Canadian public corporations. Germany's Forschungszulage has been expanded three times since 2020, with the maximum allowance increasing from EUR 500K to EUR 3.5M for SMEs (EUR 4.2M from 2026). [src2, src3, src5, src6, src7, src10]

Key Properties

• US Section 41 credit: 20% regular credit on QREs above base amount, or 14% alternative simplified credit (ASC); qualified small business can offset up to $500K/year of payroll taxes; four-part test required (Section 174 eligible, technological in nature, qualified purpose, process of experimentation) [src1]
• US Section 174A (OBBBA): Domestic R&D expenses immediately deductible from 2025; foreign R&D amortized over 15 years; per Rev. Proc. 2025-28 (issued Aug 28, 2025), small businesses (average receipts <= $31M) can elect retroactive treatment and amend 2022-2024 returns by the earlier of July 6, 2026 (one year from OBBBA enactment) or the statute-of-limitations expiry [src2, src9]
• UK merged RDEC: 20% expenditure credit (net ~15-16.2% after corporation tax) for all company sizes from April 1, 2024; Enhanced R&D Intensive Support (ERIS) at 27% for loss-making R&D-intensive SMEs (30% intensity threshold); overseas subcontractor costs generally excluded [src3]
• France CIR: 30% credit on R&D expenses up to EUR 100M, 5% above; overseas territories get 50% on first EUR 100M; operating expense flat rate reduced to 40% of R&D salaries from 2025; patent costs and young doctor regime eliminated from February 2025 [src4]
• Canada SR&ED: 35% refundable ITC for CCPCs on first CAD 6M of QREs (enhanced expenditure limit raised from CAD 3M by Budget 2025, effective for tax years beginning on/after Dec 16, 2024 — max refundable credit CAD 2.1M); 15% non-refundable for amounts above threshold and non-CCPCs; taxable-capital phase-out raised to CAD 15M–75M; capital expenditures eligible again (property acquired on/after Dec 16, 2024); enhanced rate now extended to certain eligible Canadian public corporations [src6, src10]
• Germany Forschungszulage: 25% for large companies, 35% for SMEs; assessment base up to EUR 10M (EUR 12M from 2026); applied against income tax/corporate tax liability [src5]

Conditions

• Applies when: A company incurs expenses on qualifying research and development activities in any of the major OECD jurisdictions — including wages for researchers, supplies, contract research, and (in some jurisdictions) capital expenditure on R&D equipment
• Does NOT apply when: Activities are routine data collection, market research, quality control testing of production output, management studies, social science research, or adaptation of existing products for specific customers without technical uncertainty — these fail the qualifying activity tests in all major jurisdictions
• Confidence degrades when: Pillar Two GloBE rules (effective 2024 in 40+ jurisdictions) may reduce the net benefit of R&D credits for MNEs with consolidated revenue >= EUR 750M because qualified refundable tax credits are treated as income rather than tax reductions in GloBE ETR calculations; US state-level R&D credit rules vary significantly and can change annually

Constraints

• Each country's R&D credit is governed by domestic legislation; there is no harmonized global R&D incentive. Eligible activities, rates, and documentation requirements differ substantially [src7]
• The US OBBBA changes (Section 174A immediate expensing) apply only to domestic R&D; foreign R&D expenses must still be amortized over 15 years under Section 174 [src2]
• Starting tax year 2026, IRS requires business-component-level documentation as a mandatory filing requirement for Section 41 claims per Revenue Procedure 2025-28 [src8]
• UK merged RDEC generally excludes costs of overseas subcontractors and externally provided workers from April 2024 — forcing companies to reassess R&D supply chains [src3]
• From 18 May 2026, all UK R&D claim agents must register with HMRC, and a new 12-month targeted Advance Assurance pilot opens (HMRC reviews up to two technical areas of a single project, aiming to respond within 40 calendar days) — procedural changes that affect how claims are prepared and de-risked [src11]
• France eliminated the young doctor regime and patent-related expenses from CIR eligibility effective February 15, 2025; the 2026 Finance Law (adopted Feb 2, 2026) kept the 30% rate and core parameters unchanged but parliament added a clawback requiring repayment of CIR claimed in the prior three years if productive activity is relocated abroad [src4, src12]

Rationale

R&D tax credits exist because private-sector R&D generates positive externalities (knowledge spillovers, technological progress, productivity gains) that benefit society beyond the investing firm, leading to underinvestment relative to the social optimum. Tax incentives reduce the after-tax cost of R&D, narrowing the gap between private and social returns. The OECD estimates that for every $1 of foregone tax revenue through R&D incentives, business R&D spending increases by $1.00-$1.40. Jurisdictional competition for R&D investment has driven an expansion of incentive generosity over the past two decades, though Pillar Two's global minimum tax introduces a countervailing force by limiting the tax benefit of excessive incentive stacking. [src5, src7]

Framework Selection Decision Tree

START — User needs R&D tax credit guidance
├── Which jurisdiction?
│   ├── United States
│   │   ├── Qualifying activities → Four-part test (Section 174 eligible, technological, qualified purpose, process of experimentation)
│   │   ├── Credit calculation → Regular method (20% above base) or ASC (14%)
│   │   ├── R&D expense deduction → Section 174A immediate expensing (domestic) or 15-year amortization (foreign)
│   │   └── Small business? (≤ $5M revenue, < 5 years) → Payroll tax offset up to $500K/year
│   ├── United Kingdom
│   │   ├── Company size and R&D intensity?
│   │   │   ├── Loss-making SME with ≥ 30% R&D intensity → ERIS (27% payable credit)
│   │   │   └── All other companies → Merged RDEC (20% credit, net ~15-16.2%)
│   │   └── Subcontractor location? → Overseas costs generally excluded from April 2024
│   ├── France
│   │   ├── R&D expenses ≤ EUR 100M → 30% CIR credit
│   │   └── R&D expenses > EUR 100M → 5% on excess
│   ├── Canada
│   │   ├── CCPC with ≤ CAD 6M QREs → 35% refundable ITC (enhanced limit raised from CAD 3M, Budget 2025)
│   │   └── Non-CCPC or above threshold → 15% non-refundable ITC (certain eligible public corporations now also access the enhanced 35% rate)
│   ├── Germany
│   │   └── SME? → 35% Forschungszulage on up to EUR 10M (EUR 12M from 2026)
│   │       └── Large company → 25% on same base
│   └── Australia
│       ├── Turnover < AUD 20M → 43.5% refundable offset
│       └── Turnover ≥ AUD 20M → Non-refundable offset at marginal rate + increment
├── Cross-border R&D?
│   ├── YES → Consider transfer pricing implications for intercompany R&D charges
│   │   └── See: compliance/tax/transfer-pricing-basics/2026
│   └── NO → Apply single-jurisdiction rules above
└── Group revenue ≥ EUR 750M?
    ├── YES → Factor Pillar Two GloBE ETR impact on net credit benefit
    └── NO → Not subject to Pillar Two; full credit benefit applies

Application Checklist

Step 1: Identify qualifying R&D activities

• Inputs needed: Description of all R&D projects, technical objectives, uncertainties encountered, experiments conducted, and outcomes achieved
• Output: List of projects that meet the jurisdiction's qualifying activity test (e.g., US four-part test, UK "advance in science or technology", France "original research extending state of the art")
• Constraint: Activities must involve genuine technical uncertainty and a systematic process of experimentation; routine engineering, cosmetic design changes, and market research never qualify in any jurisdiction [src1, src3]

Step 2: Calculate eligible expenditures

• Inputs needed: Detailed breakdown of wages, supplies, contract research costs, and (where applicable) capital expenditure and overhead allocations attributable to qualifying activities
• Output: Total qualified research expenditures (QREs) by category and jurisdiction
• Constraint: US QREs include only wages for qualified services, supplies consumed in research, and 65% of contract research costs; UK merged RDEC excludes most overseas subcontractor costs from April 2024; France CIR operating expense flat rate is 40% of R&D personnel costs (reduced from 43% in 2025) [src1, src3, src4]

Step 3: Compute the credit and file claims

• Inputs needed: QRE totals, base amounts (US regular method requires historical comparison), entity classification (SME/large), applicable rates
• Output: Credit amount per jurisdiction, net tax benefit after considering interaction with income deductions and Pillar Two (if applicable)
• Constraint: US starting tax year 2026 requires mandatory business-component-level substantiation per Revenue Procedure 2025-28; UK claims must be filed within two years of the end of the accounting period; France CIR declared on form 2069-A by May 15 following the calendar year [src2, src3, src8]

Step 4: Maintain documentation and prepare for audit

• Inputs needed: Project records, time-tracking data, financial records, technical narratives, contracts with subcontractors
• Output: Contemporaneous documentation package meeting each jurisdiction's requirements
• Constraint: Documentation must exist before filing deadlines — post-hoc reconstruction is a major audit red flag and may not satisfy penalty protection requirements. The IRS is increasing audit rates for large corporations to 22.6% by tax year 2026, with R&D claims a stated priority [src1, src8]

Anti-Patterns

Wrong: Claiming R&D credits without the four-part test analysis (US)

Companies claim Section 41 credits based on general "innovation" spending without documenting that each business component meets all four parts of the qualifying test. The IRS systematically disallows credits lacking business-component-level substantiation, and starting 2026, incomplete documentation is grounds for claim rejection at filing. [src1, src8]

Correct: Apply the four-part test at the business component level

For each claimed project, document the specific technical uncertainty, the systematic alternatives evaluated, the technological nature of the work, and the qualified purpose (new or improved function, performance, reliability, or quality). Maintain contemporaneous records of each element before filing. [src1]

Wrong: Assuming overseas R&D subcontractor costs qualify for UK relief

Companies with distributed R&D teams continue claiming costs of overseas subcontractors under the merged RDEC scheme. Since April 1, 2024, the UK generally excludes R&D performed by subcontractors and externally provided workers based outside the UK, significantly reducing claims for companies with offshore development centers. [src3]

Correct: Restructure R&D supply chains or adjust claims

Review subcontractor and EPW arrangements. Only costs for UK-based activities qualify under the merged scheme (with limited exceptions for conditions not replicable in the UK). Adjust claims accordingly or restructure R&D operations to preserve relief eligibility. [src3]

Wrong: Double-counting R&D expenses across credit and deduction regimes

In the US, some companies attempt to claim the full Section 174A immediate deduction and the full Section 41 credit on the same expenses without the required Section 280C adjustment. Section 280C(c) requires taxpayers to either reduce the deduction by the credit amount or elect a reduced credit. [src2]

Correct: Apply the Section 280C election consistently

Choose between reducing the Section 174A deduction by the Section 41 credit amount or electing the reduced credit under Section 280C(c)(3). Most companies elect the reduced credit because it preserves the full deduction and simplifies compliance. Document the election on each year's return. [src2, src8]

Counter-Arguments

• The net benefit of R&D credits may be lower than headline rates suggest after accounting for compliance costs. Mid-market companies (revenue $10-100M) spend 3-8% of their credit value on compliance and advisory fees, and the administrative burden of the US four-part test at business-component level is substantial. [src8]
• Pillar Two's GloBE rules may reduce the effective value of R&D credits for large MNEs. Qualified refundable credits are treated as income in GloBE ETR calculations, which preserves their benefit, but non-refundable credits reduce GloBE ETR and may trigger top-up taxes in other jurisdictions. [src7]
• Some economists argue that R&D tax credits primarily subsidize R&D that firms would have performed anyway (deadweight loss), particularly for large companies with established R&D programs. The OECD's estimate of $1.00-$1.40 additional R&D per $1 of foregone revenue is an average that masks significant variation. [src7]

Common Misconceptions

Misconception: R&D tax credits are only for companies doing "laboratory research" or developing new products from scratch.
Reality: In all major jurisdictions, R&D credits cover process improvements, software development, manufacturing optimization, and any activity involving technical uncertainty and systematic experimentation. The US four-part test does not require a laboratory setting. [src1]

Misconception: The US OBBBA restored the old pre-2022 rules exactly — everything is back to how it was.
Reality: The OBBBA created a new Section 174A (separate from old Section 174) that applies only to domestic R&D expenses. Foreign R&D expenses are still subject to 15-year amortization under Section 174. Additionally, new mandatory information reporting requirements apply starting tax year 2026. Small businesses (average receipts <= $31M) get retroactive relief for 2022-2024 by electing under Rev. Proc. 2025-28 and amending returns by the earlier of July 6, 2026 or the statute-of-limitations expiry, but larger companies can only accelerate remaining unamortized domestic balances over 2025-2026. [src2, src8, src9]

Misconception: The UK merged scheme pays out 20% of R&D costs as cash.
Reality: The 20% RDEC rate is an expenditure credit that is itself taxable. After corporation tax at 25%, the net benefit is approximately 15%. Only loss-making R&D-intensive SMEs qualifying for ERIS receive the more generous 27% payable credit. Additionally, costs of overseas subcontractors are generally excluded from April 2024. [src3]

Misconception: France's CIR is capped at EUR 100 million, so spending above that receives nothing.
Reality: The CIR applies a 30% rate on the first EUR 100M and a 5% rate on expenses above EUR 100M — it is not a cliff; relief continues at the reduced rate. The 2025 reforms eliminated patent costs and the young doctor bonus from eligible expenses, but the 2026 Finance Law (adopted 2 February 2026) confirmed the 30% rate and core parameters unchanged for 2026. [src4, src12]

Misconception: Canada's SR&ED enhanced 35% refundable credit is still limited to the first CAD 3M of expenditures and is available only to private (CCPC) companies.
Reality: Budget 2025 raised the enhanced expenditure limit to CAD 6M (effective for tax years beginning on or after Dec 16, 2024), lifted the taxable-capital phase-out range to CAD 15M–75M, reinstated capital-expenditure eligibility, and for the first time extended the enhanced 35% refundable credit to certain eligible Canadian public corporations. [src10]

Comparison with Similar Rules

When This Matters

Fetch this rule when a user asks about R&D tax credits in any jurisdiction, the US Section 41 research credit or Section 174/174A R&D expensing rules, the UK RDEC merged scheme or ERIS, the French CIR, Canadian SR&ED, German Forschungszulage, the OBBBA impact on R&D deductions, qualifying research activities and the four-part test, or comparative R&D tax incentive rates across countries.